These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 15885795)

  • 1. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review.
    Olthoff CM; Schouten JS; van de Borne BW; Webers CA
    Ophthalmology; 2005 Jun; 112(6):953-61. PubMed ID: 15885795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France].
    Bron A; Nordmann JP; Baudouin C; Rouland JF; Kadi A; Sartral M
    J Fr Ophtalmol; 2003 Nov; 26(9):895-903. PubMed ID: 14631273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology.
    Dueker DK; Singh K; Lin SC; Fechtner RD; Minckler DS; Samples JR; Schuman JS
    Ophthalmology; 2007 Sep; 114(9):1779-87. PubMed ID: 17822980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: why do two studies have different results?
    Parrish RK
    Curr Opin Ophthalmol; 2006 Apr; 17(2):138-41. PubMed ID: 16552248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
    Gugleta K
    Curr Med Res Opin; 2010 Jun; 26(6):1255-67. PubMed ID: 20350146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
    Katz LJ; Simmons ST; Craven ER
    Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.
    Bengtsson B; Leske MC; Hyman L; Heijl A;
    Ophthalmology; 2007 Feb; 114(2):205-9. PubMed ID: 17097736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients.
    Day DG; Sharpe ED; Atkinson MJ; Stewart JA; Stewart WC
    Eye (Lond); 2006 May; 20(5):583-90. PubMed ID: 15933751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noncompliance with medical treatment among glaucoma patients in Oman--a cross-sectional descriptive study.
    Khandekar R; Shama Mel-S; Mohammed AJ
    Ophthalmic Epidemiol; 2005 Oct; 12(5):303-9. PubMed ID: 16272050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence and adherence with topical glaucoma therapy.
    Nordstrom BL; Friedman DS; Mozaffari E; Quigley HA; Walker AM
    Am J Ophthalmol; 2005 Oct; 140(4):598-606. PubMed ID: 16226511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.
    van der Valk R; Webers CA; Schouten JS; Zeegers MP; Hendrikse F; Prins MH
    Ophthalmology; 2005 Jul; 112(7):1177-85. PubMed ID: 15921747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study.
    Quigley HA; Friedman DS; Hahn SR
    Ophthalmology; 2007 Sep; 114(9):1599-606. PubMed ID: 17572498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension.
    Martinez A; Sanchez M
    Expert Opin Pharmacother; 2008 Jan; 9(1):137-43. PubMed ID: 18076345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance of Glaucoma Patients to Ocular Hypotensive Medications Among the Saudi Population.
    Osman EA; Alqarni BA; AlHasani SS; Al Harbi SS; Gikandi PW; Mousa A
    J Ocul Pharmacol Ther; 2016; 32(1):50-4. PubMed ID: 26600401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
    McCarty CA; Mukesh BN; Kitchner TE; Hubbard WC; Wilke RA; Burmester JK; Patchett RB
    J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.
    Trattler W; Noecker RJ; Earl ML
    Adv Ther; 2008 Mar; 25(3):179-89. PubMed ID: 18351298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
    Friström B; Uusitalo H
    Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular hypotensive medications for the treatment of glaucoma.
    Lee DA
    Ophthalmol Clin North Am; 2005 Dec; 18(4):529-38. PubMed ID: 16314217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.